U.S. Markets open in 5 hrs 57 mins

Aeterna Zentaris Inc. (AEZS)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.80+0.46 (+19.66%)
At close: 4:00PM EDT
People also watch
KERXCYCCAVEOGALEOPXA
  • Bought 21,400 shares of this in the premarket yesterday at $1.51. Still holding onto all the shares and extremely happy. Already up almost 30 grand
  • Give me a thumbs up to see 3.16 by the finish today!!!
  • This is why I taught myself how to script. There are hundreds of AEZS opportunities daily... run a scanner in the premarket and have buying power available = profit.
  • Today is Huge for AEZS...this is a stable company with Major growth, great financials and now positive FDA Submission News which = $$$ for the company. Soon the Upgrades and Big Name Hedge funds will start buying in now as this stock is definitely on the radar now. This stock should continue to trend up as the day goes on and even more once the upgrades start and the 1yr target increases Big Time...Baker Brothers Advisors, RA Capital and Broadfin Capital, etc. Great fundamentals, management and guidance that's in favor of share holders plus larger companies that my want to buyout AEZS.
  • Based on momentum, watch for $3.50 during premarket tomorrow, followed by an early morning run up nearing $4.00 with profit taking in the afternoon.
  • After hours will be on fire
  • After hours announcement that Dodd is canned and replaced by an experienced company seller tells me that we have several suitors in the wings.
    Company will announce a sale by Thanksgiving!
    Gobble - Gobble - Gobble!
  • DCTH will soar aftermarket!! FDA approved patent on the 18th, press release soon to follow!
  • How much more upside does AEZS have to go, who knows with that Volume horsepower!!! ACRX do some digging, with an October 12, 2017, PDUFA date coming up, just another biotech of interest with significant potential upside, albeit no guarantees in the biotech world:

    https://seekingalpha.com/article/4087901-acelrx-undervalued-heading-phase-3-catalyst

    AcelRx: Undervalued Heading Into A Phase 3 Catalyst
    AcelRx is a relatively unknown biotech company focused on the development and eventual commercialization of treatments for moderate-severe acute pain. Shares ar
    seekingalpha.com
  • The Huge .40 spike to $3.26 earlier means there is some major Institutional buying going on now to maintain the stock price above $3. As I stated yesterday, the stock price should continue rise on the heels of great FDA news and a quicker path to FDA Approval.
  • Can i still get in there ?
  • NDA accepted, up big AH, should do well tomorrow. Stock doubles before the end of the year!
  • it will come down still wait for it
  • Looks like it'll be an interesting Friday at opening ! Seems like investors like the after hour news!!!! May see a 50% gain and follow thru on Monday!!
  • This stock will be much slower tomorrow, but it'll still rise. I predict a 4-6% increase. Based on old patterns.
  • Missed US FDA approval in September last year but now sure get it by November 2017, hitting US Market with ONLY DRUG FOR AGHD approved by US FDA !!!
    Macrilen™, has been granted orphan drug designation by the FDA for diagnosis of Adult Growth Hormone Deficiency (“AGHD”). The Company owns the worldwide rights to this patented compound and has significant patent protection left. The Company’s U.S. composition of matter patent expires in 2022 and its U.S. utility patent runs through 2027. If approved, Macrilen™ will be the only FDA-approved drug indicated for use in assessing AGHD.

    The Company believes that, in the US alone, approximately 36,000 confirmatory tests for AGHD are conducted each year, which represents the target market at commercialization. Furthermore, the Company believes that Macrilen™, if it is approved, is likely to be rapidly adopted by physicians as the preferred means of evaluating AGHD for the following reasons:

    Unlike the insulin tolerance test (“ITT”), currently the most often means of evaluating AGHD, the evaluation of AGHD using Macrile™ does not require the patient to become hypoglycemic;
    Macrilen™ is administered orally, while the ITT requires an intravenous infusion of insulin;
    the evaluation of AGHD using Macrilen™ is much less time consuming and labor intensive than the ITT and, therefore, it is less expensive to conduct; and
    the evaluation can be conducted in the physician’s office rather than in a hospital setting.
    The Company intends to commercialize the product in the United States and is considering out-licensing the commercial rights in non-US territories.
  • "02.77%" institutional ownership( Nasdaq data) = no slam dunk or guaranteed approval
  • lol on those who sold and bailed out
  • The real battle has begun. We'll see who wins
  • Shorts make me sick.